Guobang Pharma Ltd (605507) — Capital Reinvestment Ratio
Latest as of September 2025:
0.36x
Guobang Pharma Ltd (605507) has a Capital Reinvestment Ratio of 0.36x as of September 2025, meaning it reinvests 0% of its operating cash flow (CN¥311.27 Million) in capital expenditures (CN¥110.58 Million). See 605507 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.36x
Capex / Operating Cash Flow
Operating Cash Flow
CN¥311.27 Million
CNY
Capital Expenditures
CN¥110.58 Million
CNY
Data as of
Sep 2025
Most recent filing
Guobang Pharma Ltd Capital Reinvestment Ratio (2017–2025)
This chart tracks Guobang Pharma Ltd's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for Guobang Pharma Ltd (2017–2025)
Year-by-year Capital Reinvestment Ratio for Guobang Pharma Ltd from 2017 to 2025. For live market cap and broader valuation context, see Guobang Pharma Ltd market capitalisation.
| Year | Reinvestment Ratio | Operating CF (CNY) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.50x | CN¥559.28 Million | CN¥277.71 Million | ▼ -16.3% |
| 2024 | 0.59x | CN¥706.41 Million | CN¥419.12 Million | ▼ -59.0% |
| 2023 | 1.45x | CN¥516.76 Million | CN¥748.44 Million | ▲ +83.4% |
| 2022 | 0.79x | CN¥1.02 Billion | CN¥803.12 Million | ▲ +16.5% |
| 2020 | 0.68x | CN¥767.70 Million | CN¥520.16 Million | ▼ -50.6% |
| 2019 | 1.37x | CN¥440.86 Million | CN¥605.18 Million | ▲ +355.5% |
| 2018 | 0.30x | CN¥541.68 Million | CN¥163.24 Million | ▼ -73.7% |
| 2017 | 1.14x | CN¥148.03 Million | CN¥169.48 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow